Skip to content
Search

Latest Stories

Top Stories

Three major health care battles taking shape in 2024

People protesting Dobbs decision

People protested on the first anniversary of the Supreme Court's June 2022 decision in the Dobbs case. The court may further limit abortion rights this year.

Celal Gunes/Anadolu Agency via Getty Images

Pearl is a clinical professor of plastic surgery at the Stanford University School of Medicine and is on the faculty of the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Modern medicine, for most of its history, has operated within a collegial environment — an industry of civility where physicians, pharmaceutical companies and hospitals stayed in their lanes and out of each other’s business.

Times have changed as health care has taken a 180-degree turn. This year will be characterized by cutthroat competition and intense disputes played out in public. And as the once harmonious world of health care braces for battle, three critical struggles take center stage. Each promises controversy and profound implications for the future of medicine.

The first battle involves abortion rights.


For nearly 50 years — from the landmark Roe v. Wade decision in 1973 to its overruling by the 2022 Dobbs case — abortion decisions were the province of women and their doctors. This dynamic has changed in nearly half the states.

This spring, the Supreme Court is set to hear another pivotal case. It concerns mifepristone, an important drug for medical abortions. The ruling, expected in June, will significantly impact women’s rights, as well as federal regulatory bodies like the Food and Drug Administration.

Sign up for The Fulcrum newsletter

Traditionally, abortions were surgical procedures. Today, over half are medically induced, primarily using a two-drug combination that includes mifepristone. Since its approval in 2000, mifepristone has been prescribed to over 5 million women, and it boasts an excellent safety record.

But anti-abortion groups have proposed stringent legal restrictions: reducing the administration window from 10 to seven weeks post-conception, banning distribution of the drug by mail, and mandating three in-person doctor visits, a burdensome requirement for many.

While physicians would still be allowed to prescribe misoprostol (the second drug in the regimen), its effectiveness alone pales in comparison to the two-drug combo.

Should the Supreme Court overrule the FDA’s clinical expertise on these matters, abortion activists fear the floodgates will open, inviting new challenges against other established medications like birth control.

In response, several states have fortified abortion rights through ballot initiatives, a trend expected to gain momentum in the November elections. This legislative action underscores a significant public-opinion break from the Supreme Court’s stance. In fact, a survey published in Nature Human Behavior reveals that 60 percent of Americans support legal abortion.

Who will win this battle? That’s unclear. Traditionally, the court’s rulings have mirrored public opinion on key social issues, but the gap is large on abortion rights. This sets the stage for an even fiercer clash in years to come. A Supreme Court ruling that renders abortion unconstitutional would contradict the principles outlined in Dobbs and recent protections passed by the states. As a result, America’s divide on abortion rights is poised to deepen.

The second battle involves the use of generative AI in medicine.

A year after ChatGPT’s release, artificial intelligence is already reshaping entire industries. In health care, insurers are leveraging AI to speed up and intensify claim denials, prompting providers to counter with AI-assisted appeals.

Beyond corporate skirmishes, the most profound AI conflict involves the doctor-patient relationship. Physicians, already vexed by patients who self-diagnose with “Dr. Google,” find themselves unsure whether generative AI will be friend or foe.

Studies conclude that generative AI can already diagnose and recommend treatments with remarkable accuracy and empathy, surpassing human doctors in ever-more ways. And unlike traditional search engines, generative AI doesn’t just spit out unfiltered, generic information. It provides nuanced and personalized insights based on terabytes of up-to-date medical research and the patient’s own health data.

Who will win this battle? Whoever embraces these tools faster and more intelligently. While doctors are already taking advantage of AI’s administrative benefits (billing, notetaking and data entry), they’re apprehensive that ChatGPT will lead to errors if used for patient care. But five years from now, with ChatGPT predicted to be 30 times more powerful, generative AI systems will become safer, more reliable and integral to medical care. Advanced tools, interfacing with wearables and electronic health records, will aid with disease management, diagnosis and chronic-condition monitoring, enhancing clinical outcomes, and overall health.

The final battle features a tug-of-war over health care pricing.

From routine doctor visits to complex hospital stays and drug prescriptions, every aspect of U.S. health care is getting more expensive. That’s not news to most Americans, half of whom say it is very or somewhat difficult to afford health care costs.

Throughout U.S. health care, financial pressures are increasing. Hospitals are consolidating. Nurses are striking. And thousands of physicians have sold their medical practices to private equity firms.

This trend will continue in 2024 and likely drive up prices, as much as 30 percent higher for many specialties.

Drug spending, meanwhile, will soar in 2024 as weight-loss drugs (costing roughly $12,000 a year) become increasingly available. A groundbreaking sickle cell disease treatment is projected to cost nearly $3 million upon release. This year, Big Pharma will bolster its efforts to delay or overturn legislation that would allow the centers for Medicare & Medicaid Services to negotiate prices for 10 of the most expensive outpatient drugs starting in 2026.

Who will win the pricing battle? That’s up to voters. With national health care spending expected to rise from $4 trillion now to $7 trillion by 2031, the upcoming election will be pivotal in steering the financial strategy. A Republican surge could mean tighter controls on Medicare and Medicaid and relaxed insurance regulations, whereas a Democratic sweep could lead to increased taxes, especially on the wealthy. A divided government, however, would stall significant reforms, exacerbating the crisis of unaffordability.

So, is peace possible? Amid the strife, hope glimmers: The rise of ChatGPT and other generative AI technologies holds promise for empowering patients and improving clinical outcomes. The debate over abortion rights, while deeply polarizing, might eventually find resolution in a legislative middle ground that echoes Roe’s protections with some restrictions on how late in pregnancy procedures can be performed.

Unfortunately, some problems need to get worse before they can get better. I predict the affordability of health care will be one of them. My New Year’s request is to not shoot the messenger.

Read More

Man stepping on ripped poster

A man treads on a picture of Syria's ousted president, Bashar al-Assad, as people enter his residence in Damascus on Dec. 8.

Omar Haj Kadour/AFP via Getty Images

With Assad out, this is what we must do to help save Syria

This was a long day coming, and frankly one I never thought I’d see.

Thirteen years ago, Syria’s Bashar Assad unleashed a reign of unmitigated terror on his own people, in response to protests of his inhumane Ba’athist government.

Keep ReadingShow less
Men and a boy walking through a hallway

Vivek Ramaswamy and Elon Musk, with his son X, depart the Capitol on Dec. 5.

Craig Hudson for The Washington Post via Getty Images

Will DOGE promote efficiency for its own sake?

This is the first entry in a series on the Department of Government Efficiency, an advisory board created by President-elect Donald Trump to recommend cuts in government spending and regulations. DOGE, which is spearheaded by Elon Musk and Vivek Ramaswamy, has generated quite a bit of discussion in recent weeks.

The goal of making government efficient is certainly an enviable one indeed. However, the potential for personal biases or political agendas to interfere with the process must be monitored.

As DOGE suggests cuts to wasteful spending and ways to streamline government operations, potentially saving billions of dollars, The Fulcrum will focus on the pros and cons.

We will not shy away from DOGE’s most controversial proposals and will call attention to dangerous thinking that threatens our democracy when we see it. However, in doing so, we are committing to not employing accusations, innuendos or misinformation. We will advocate for intellectual honesty to inform and persuade effectively.

The new Department of Government Efficiency, an advisory board to be headed by Elon Musk and Vivek Ramaswamy, is designed to cut resources and avoid waste — indeed to save money. Few can argue this isn't a laudable goal as most Americans have experienced the inefficiencies and waste of various government agencies.

Sign up for The Fulcrum newsletter

Keep ReadingShow less
From left: Volodymyr Zelenskyy, Emmanuel Macron, Donald Trump

President-elect Donald Trump spoke with Ukrainian President Volodymyr Zelenskyy and French President Emmanuel Macron on Dec. 7. No one will be able to restrain Trump's foreign policy efforts.

The true Trump threat

Many Americans fear what Donald Trump will do after assuming the presidency in January — and understandably so. Trump's pathological self-absorption has no place in American government, let alone at its very top.

But the specific type of threat Trump poses is often misunderstood. Like all presidents, his domestic powers are limited. He will face stiff resistance at the federal, state and local levels of government.

Keep ReadingShow less
Donald Trump and Tulsi Gabbard on stage

President-elect Donald Trump has nominated former Rep. Tulsi Gabbard to be the director of national intelligence.

Adam J. Dewey/Anadolu via Getty Images

How a director of national intelligence helps a president stay on top of threats from around the world

In all the arguments over whether President-elect Donald Trump’s choice for director of national intelligence is fit for the job, it’s easy to lose sight of why it matters.

It matters a lot. To speak of telling truth to power seems terribly old-fashioned these days, but as a veteran of White House intelligence operations, I know that is the essence of the job.

Keep ReadingShow less